View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 4, 2022

Altimmune commences enrolment in Phase II trial of obesity treatment

The relative change from baseline in body weight at 48 weeks following pemvidutide treatment is the trial’s primary endpoint.

Altimmune has enrolled the first subject in the Phase II MOMENTUM clinical trial of its investigational therapy, pemvidutide, in participants with obesity or overweight. 

A new peptide-based GLP-1/glucagon dual receptor agonist, pemvidutide is being developed to treat obesity and non-alcoholic steatohepatitis (NASH). 

The randomised, placebo-controlled trial will analyse the safety and efficacy of pemvidutide versus placebo in nearly 320 non-diabetic individuals.

Being carried out in nearly 25 study centres in the US, the trial will randomise the subjects into a 1:1:1:1 ratio to receive either 1.2, 1.8, 2.4mg doses of pemvidutide or placebo every week for 48 weeks. 

The relative variation from baseline in body weight at 48 weeks is the primary endpoint of the trial. 

Further readouts such as metabolic and lipid profiles, cardiovascular measures and glucose homeostasis will also be analysed.

The company intends to carry out an interim assessment to evaluate variations in body weight after 24 weeks and anticipates data readout in the fourth quarter of this year.

According to data from a Phase I trial, obese individuals had an average weight loss of 10.3% without diet or lifestyle modification following administration of subcutaneous doses of pemvidutide for 12 weeks.

Altimmune chief medical officer Dr Scott Harris said: “Initiation of the Phase II MOMENTUM obesity trial marks an important milestone in the development of pemvidutide. 

“Built on a foundation of compelling Phase I clinical data, we see a great potential for pemvidutide to address the serious and widespread disease of obesity and its debilitating consequences.”

Meanwhile, the company concluded subject enrolment in the 12-week Phase Ib trial of pemvidutide in non-alcoholic fatty liver disease (NAFLD) patients.

In May last year, Altimmune reported preclinical data, where its single-dose intranasal Covid-19 vaccine, AdCOVID, showed positive results, with no detectable levels of virus in the lungs of vaccinated mice after challenge with the SARS-CoV-2 virus.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy